Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Capricor Therapeutics Inc
CAPR
Healthcare
Biotechnology
Capricor Therapeutics, Inc. is a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment and prevention of rare diseases. The Company's program is focused on the development and commercialization of a cell therapy technology comprised of cardiosphere-derived cells (CDCs) for the treatment of Duchenne muscular dystrophy (DMD). Its lead product...
candidate, CAP-1002, is an allogeneic cardiac-derived cell therapy. CAP-1002 is advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy (DMD). CAP-1002 demonstrates immunomodulatory, antifibrotic, and regenerative actions specifically tailored for dystrophinopathies and heart disease. The Company leverages its exosome technology, using its StealthX platform in preclinical development focused on the areas of vaccinology, targeted delivery of oligonucleotides, proteins and small molecule therapeutics to potentially treat and prevent a diverse array of diseases.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (NDAQ:CAPR)
New Post
View:
Posts & Comments
Threaded Posts
(200)
•••
whytestocks
X
View Profile
View Bullboard History
Post by
whytestocks
on Oct 17, 2024 6:00pm
Capricor Therapeutics Announces Pricing of Approximately $75
Breaking News: $CAPR Capricor Therapeutics Announces Pricing of Approximately $75 Million Public Offering of Common StockSAN DIEGO, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ
...more
(200)
•••
whytestocks
X
View Profile
View Bullboard History
Post by
whytestocks
on Oct 11, 2024 10:03am
Capricor Therapeutics Announces Positive Long-Term Data from
News; $CAPR Capricor Therapeutics Announces Positive Long-Term Data from HOPE-2 OLE Study in Duchenne Muscular Dystrophy at 2024 World Muscle Society Congress-Data Supports Deramiocel@s Sustained
...more
BioVaxys' DPX Exhibits Superior Immune System Activation Compared to Aqueous and Emulsion-Based Antigen Delivery Systems
posted Oct 31, 2024 9:00am by
BioVaxys Technology Corp.
-
|
"BioVaxys is at the forefront of a significant shift in the drug delivery landscape," James Passin, CEO of BioVaxys, stated, "These groundbreaking study results validate our strategic position in an important segment of the multi-billion drug delivery market. DPX not only outperforms current antigen delivery solutions but also demonstrate ...read more
(200)
•••
whytestocks
X
View Profile
View Bullboard History
Post by
whytestocks
on Sep 25, 2024 10:15am
CAPR Price Target Alert: $25.00. Issued by Maxim Group
Just In: $CAPR CAPR Price Target Alert: $25.00. Issued by Maxim Group2024-09-25 10:00:03 ET Jason McCarthy from Maxim Group issued a price target of $25.00 for CAPR on 2024-09-25 08:12:00. The
...more
(200)
•••
whytestocks
X
View Profile
View Bullboard History
Post by
whytestocks
on Sep 24, 2024 10:32am
Capricor Therapeutics Announces Intent to File Biologics Lic
BREAKING NEWS: $CAPR Capricor Therapeutics Announces Intent to File Biologics License Application for Full Approval of Deramiocel for the Treatment of Duchenne Muscular Dystrophy Cardiomyopathy-BLA to
...more
(200)
•••
whytestocks
X
View Profile
View Bullboard History
Post by
whytestocks
on Sep 17, 2024 11:45am
Capricor Therapeutics Signs Binding Term Sheet with Nippon S
BREAKING NEWS: $CAPR Capricor Therapeutics Signs Binding Term Sheet with Nippon Shinyaku for European Expansion and Commercialization of Deramiocel for the Treatment of Duchenne Muscular Dystrophy
...more
(200)
•••
whytestocks
X
View Profile
View Bullboard History
Post by
whytestocks
on Jun 13, 2024 2:45pm
Pfizer Phase III DMD Gene Therapy Study Misses Goal | Benzin
Breaking News: $CAPR Pfizer Phase III DMD Gene Therapy Study Misses Goal | BenzingaPfizer (NYSE: PFE) announced that a phase III study on its mini-dystrophin gene therapy fordadistrogene movaparvovec
...more
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
Tribe Property Technologies Provides Update on Tribe Home, Demonstrating Increased Efficiencies with Property Management Platform
Learn how to Trade on the U.S. Election and other Economic and Environmental Events
Major Copper-Gold Discovery Revealed! High-Grade Rock Samples Signal Untapped Potential
Canadian Miner Launches Private Placement for Ambitious Alaskan Gold Project
Be a Part of a Gold Company Before it Catches the Attention of the Market’s Major Players
A Swedish Solution to Break European Dependency on China for Critical Raw Materials
Breakthrough in Cancer Vaccine Tech: New Platform Outshines Traditional Methods in Immune Activation
Prospera Energy corporate update: 3 years of strategic restructuring, recovery and future growth
Discover Options Trading Strategies to Minimize your Tax Burden